MX2015007678A - Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales. - Google Patents

Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.

Info

Publication number
MX2015007678A
MX2015007678A MX2015007678A MX2015007678A MX2015007678A MX 2015007678 A MX2015007678 A MX 2015007678A MX 2015007678 A MX2015007678 A MX 2015007678A MX 2015007678 A MX2015007678 A MX 2015007678A MX 2015007678 A MX2015007678 A MX 2015007678A
Authority
MX
Mexico
Prior art keywords
glatiramer acetate
transmucosal delivery
percent
weight
provides
Prior art date
Application number
MX2015007678A
Other languages
English (en)
Spanish (es)
Inventor
Ursula Geister
Stephan Schweizer
Martina Buerger
Ralph Stefan
Gerald Huber
Tanja Pries
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2015007678A publication Critical patent/MX2015007678A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015007678A 2012-12-21 2013-12-20 Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales. MX2015007678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (1)

Publication Number Publication Date
MX2015007678A true MX2015007678A (es) 2015-09-07

Family

ID=50979257

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007678A MX2015007678A (es) 2012-12-21 2013-12-20 Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.

Country Status (15)

Country Link
US (1) US20160193276A1 (enExample)
EP (1) EP2934492A4 (enExample)
JP (1) JP2016503803A (enExample)
KR (1) KR20150111918A (enExample)
CN (1) CN104869983A (enExample)
AU (1) AU2013361053A1 (enExample)
BR (1) BR112015014095A2 (enExample)
CA (1) CA2895359A1 (enExample)
EA (1) EA201591188A1 (enExample)
HK (2) HK1214523A1 (enExample)
IL (1) IL239280A0 (enExample)
MX (1) MX2015007678A (enExample)
SG (1) SG11201504422XA (enExample)
WO (1) WO2014100639A1 (enExample)
ZA (1) ZA201505049B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷(glatiramer)醋酸鹽之臨床反應之單核苷酸多型性之判定
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
WO2017138645A1 (ja) * 2016-02-12 2017-08-17 テイカ製薬株式会社 乾式造粒物及び該乾式造粒物を含有する固形製剤並びにそれらの製造方法
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
EA005537B1 (ru) * 2001-07-10 2005-04-28 Тева Фармасьютикал Индастриес Лтд. Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
CA2596664A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
AU2005338461A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
BRPI0620578A2 (pt) * 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
EP2526934B1 (en) * 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Also Published As

Publication number Publication date
CA2895359A1 (en) 2014-06-26
JP2016503803A (ja) 2016-02-08
AU2013361053A1 (en) 2015-07-30
SG11201504422XA (en) 2015-07-30
CN104869983A (zh) 2015-08-26
EA201591188A1 (ru) 2016-04-29
IL239280A0 (en) 2015-07-30
WO2014100639A1 (en) 2014-06-26
HK1214134A1 (zh) 2016-07-22
US20160193276A1 (en) 2016-07-07
EP2934492A4 (en) 2016-08-17
EP2934492A1 (en) 2015-10-28
KR20150111918A (ko) 2015-10-06
ZA201505049B (en) 2016-10-26
HK1214523A1 (zh) 2016-07-29
BR112015014095A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
MX2015007678A (es) Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.
PH12015501439A1 (en) Oral care products comprising zinc oxide and trimethylglycine
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MY181159A (en) Sublingual and buccal film compositions
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
MX348823B (es) Formulaciones estables de linaclotida.
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX347101B (es) Forma de dosis de disolucion rapida de vacuna oral que usa almidon.
IN2014CN03214A (enExample)
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
PH12013502325A1 (en) Drug delivery system
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2015007794A (es) Suministro transmucosal de acetato de glatiramer mediante parches orales.
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
MX2015010594A (es) Esteres de testosterona de cadena larga lipobalanceados para suministro oral.
IN2014DN09240A (enExample)
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
IN2013CH01615A (enExample)
UA93515C2 (ru) Медикаментозное средство ha ochobe рутина